Jonah Feldman

Patients treated with ide-cel, Abecma for relapsed/refractory multiple myeloma affecting the central nervous system had similar outcomes to matched patients with non-CNS multiple myeloma.

Following risk management measures, ponatinib-associated adverse events in CML and ALL were shown to have decreased significantly since the drug’s approval.

Trastuzumab deruxtecan improved time to deterioration for pain and other categories, in patients with HER2 low/ultralow breast cancer.

Patients treated with enfortumab vedotin before sacituzumab govitecan had low objective response rates and median PFS, which may raise questions about this sequencing approach.

Immune engager therapies, according to a retrospective study of real-world patients, had the best rates of responses and progression-free survival in patients with multiple myeloma whose disease relapsed after treatment with idecabtagene vicleucel.

Subsequent therapies in patients with metastatic hormone-sensitive prostate cancer who were censored from primary overall survival follow-up from the ARASENS trial, according to a post hoc sensitivity analysis, confirmed the overall survival benefit derived from darolutamide plus androgen deprivation therapy and docetaxel.

Trastuzumab deruxtecan showed the longest time to next treatment in patients with HER2-positive breast cancer or with stable HER2-low disease among the primary and metastatic setting.

Patients with hepatocellular carcinoma experienced better health-related quality of life outcomes with tislelizumab vs sorafenib.

Extended follow-up data from 2 trials confirmed that larotrectinib yielded positive progression-free and overall survival outcomes for patients with NTRK-positive lung cancer.

Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.

Findings from a phase 1 trial evaluating CAR T-cell therapy in patients with solid tumors showed promising clinical benefit with the treatment strategy.

An expert from the Ohio State University Comprehensive Cancer Center discusses whether predictive biomarkers hold the potential to change endometrial prognoses.